John R Chiminski
CIK 1482197 · Executive Chair · last filed 2026-06-29
John R Chiminski is an Executive Chair who has filed 54 SEC Form 4 insider transactions across 5 companies since 2010. The most recent filing, for QDEL, was dated Jun 29, 2026. Across all open-market trades the lifetime net is −$96.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $130.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$130.6K
5
54
-$95.96M
Filer Profile
9975 SUMMERS RIDGE ROAD
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QDEL | Director | 9,352 | $13.97 | $130.6K | $0 | 4 | 2026-06-29 |
| Bruker Cellular Analysis, Inc. (CELL) Delisted | Director | 41,240 | $1.00 | $41.2K | $0 | 2 | 2023-10-03 |
| Catalent, Inc. (CTLT) Delisted | Executive Chair | 229,888 | $63.48 | $14.59M | -$96.05M | 42 | 2022-08-26 |
| Bruker Cellular Analysis, Inc. (BLI) Delisted | Director | 42,465 | $1.20 | $51.0K | $93.3K | 3 | 2022-08-01 |
| Graham Packaging Co Inc. (GRM) Delisted | Director | — | — | — | $0 | 2 | 2011-09-09 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-29 | QDEL | Grant (A) | — | $0 | EDGAR |
| 2026-06-02 | QDEL | Mixed | +6,829 | $0 | EDGAR |
| 2025-06-02 | QDEL | Grant (A) | — | $0 | EDGAR |
| 2025-05-27 | QDEL | Mixed | +2,523 | $0 | EDGAR |
| 2023-10-03 | Bruker Cellular Analysis, Inc. (CELL) Delisted | Disp (D) | −112,465 | $0 | EDGAR |
| 2023-08-01 | — | Notice (144) | −7,817 | -$367.3K | EDGAR |
| 2023-06-01 | Bruker Cellular Analysis, Inc. (CELL) Delisted | Grant (A) | +70,000 | $0 | EDGAR |
| 2022-08-26 | Catalent, Inc. (CTLT) Delisted | Mixed | +60,341 | -$4.01M | EDGAR |
| 2022-08-01 | Bruker Cellular Analysis, Inc. (BLI) Delisted | Grant (A) | +19,565 | $0 | EDGAR |
| 2022-07-28 | Catalent, Inc. (CTLT) Delisted | Mixed | +27,474 | -$1.04M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.